GlycoMimetics earns $15M milestone

GlycoMimetics (GLYC -6.1%) earns a $15M milestone payment from collaboration partner Pfizer (PFE -0.1%) for the development of GMI-1070 (rivipansel). When the first patient is dosed in the planned Phase 3 clinical trial GLYC will earn another $20M.

Rivipansel is an anti-inflammatory pan-selectin inhibitor. The companies are working on its efficacy as a treatment for vaso-occlusive crisis (VOC) of sickle cell disease. Their partnership began in late 2011.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs